13115-21-4

Usage

Uses

Used in Pharmaceutical Industry:
HYDROXYGUANIDINE SULFATE is used as a pharmaceutical compound for its role in the biosynthesis of neurotransmitters. Its function as a substrate for dopamine β-hydroxylase makes it a potential candidate for the development of treatments related to neurotransmitter imbalances and associated conditions.
Used in Research and Development:
In the field of research and development, HYDROXYGUANIDINE SULFATE is utilized as a key compound for studying the mechanisms of neurotransmitter synthesis and the role of dopamine β-hydroxylase in various biological processes. This understanding can contribute to the advancement of therapeutic strategies for neurological and psychiatric disorders.
Used in Chemical Synthesis:
HYDROXYGUANIDINE SULFATE can also be employed as a starting material or intermediate in the synthesis of other guanidine-based compounds with potential applications in various industries, such as pharmaceuticals, agrochemicals, and materials science. Its unique structural features make it a valuable building block for the development of novel molecules with specific properties and functions.

Upstream product

• 420-04-2 CYANAMID 
• 14527-26-5 2-methylisothiourea sulphate 
• 867-44-7 S-Methylisothiourea sulfate 
• 7803-49-8 hydroxylamine 

Downstream Products

• 39512-64-6 1,2,4-oxadiazol-3-amine 
• 868696-43-9 5-isobutyl-[1,2,4]oxadiazol-3-ylamine 
• 868696-42-8 5-cyclopropyl-1,2,4-oxadiazol-3-amine 
• 171006-99-8 3-amino-5-propyl-1,2,4-oxadiazole 
• 1382486-42-1 C₂₀H₁₉BrN₄O₃ 
• 1471298-01-7 (2S,5R)-2-(3-amino-1,2,4-oxadiazol-5-yl)-6-(benzyloxy)-1,6-diazabicyclo[3.2.1]octan-7-one 
• 77159-80-9 1-(2,6-Dimethylphenyl)-3-hydroxyamidinoharnstoff 
• 868696-41-7 5-isopropyl-[1,2,4]oxadiazol-3-ylamine 

Relevant academic research and scientific papers

6-SUBSTITUTED DERIVATIVES OF HEXAMETHYLENE AMILORIDE AS INHIBITORS OF uPA AND USES THEREOF

The present invention broadly relates to 6-substituted derivatives of hexamethylene amiloride, the preparation thereof, and their use in the treatment of diseases such as cancer.

1,2,4-OXADIAZOLE AND 1,2,4-THIADIAZOLE BETA-LACTAMASE INHIBITORS

β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed.

COGNITION ENHANCING COMPOUNDS AND COMPOSITIONS, METHODS OF MAKING, AND METHODS OF TREATING

The invention relates generally to muscarinic agonists, which are useful for stimulating muscarine, receptors and treating cognitive disorders. Included among the muscarinic agonists disclosed herein are oxadiazole derivatives compositions, and preparations thereof. Methods of synthesizing oxadiazole compounds also are provided. This disclosure also relates in part to compositions for enhancing cognitive function in subjects such as humans. The compositions comprising a muscarinic agonist or a pharma.ceutically suitable form thereof. This disclosure relates in part to methods of treating animals such as humans by administering such compositions.

COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING

Disclosed are muscarinic agonist compounds including oxadiazole derivatives, compositions and preparations thereof. Also disclosed are methods of synthesizing such oxadiazole compounds. Further disclosed are methods for treating a subject with said muscarinic agonists or a pharmaceutically suitable form thereof to enhance cognitive function.

COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING

Muscarinic agonists, which are useful for stimulating muscarinic receptors and treating cognitive disorders, are provided. Methods of synthesizing such agonists also are provided. Also provided are compositions for enhancing cognitive function in subjects such as humans, the compositions comprising a muscarinic agonist or a pharmaceutically suitable form thereof. Also provided are methods of treating animals such as humans by administering such compositions.

MODIFIED GUANIDINO AND AMIDINO THROMBIN INHIBITORS

Thrombin inhibitors are provided which have the formula STR1 wherein Z is a thrombin inhibitor substructure containing distal and proximal binding site residues; andR 1 is cyano, hydroxyl, alkoxy, amino, aminoalkyl or nitro.